Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 26:15:4199-4215.
doi: 10.2147/JIR.S375494. eCollection 2022.

An Overview of Neurological and Psychiatric Complications During Post-COVID Period: A Narrative Review

Affiliations
Review

An Overview of Neurological and Psychiatric Complications During Post-COVID Period: A Narrative Review

Dan Li et al. J Inflamm Res. .

Abstract

The coronavirus disease 2019 (COVID-19), induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a multi-organ and multi-system disease with high morbidity and mortality in severe cases due to respiratory failure and severe cardiovascular events. However, the various manifestations of neurological and psychiatric (N/P) systems of COVID-19 should not be neglected. Some clinical studies have reported a high risk of N/P disorders in COVID-19 and post-COVID-19 patients and that their outcomes were positively associated with the disease severity. These clinical manifestations could attribute to direct SARS-CoV-2 invasion into the central nervous system (CNS), which is often complicated by systemic hypoxia, the dysfunctional activity of the renin-angiotensin system and other relevant pathological changes. These changes may remain long term and may even lead to persistent post-COVID consequences on the CNS, such as memory, attention and focus issues, persistent headaches, lingering loss of smell and taste, enduring muscle aches and chronic fatigue. Mild confusion and coma are serious adverse outcomes of neuropathological manifestations in COVID-19 patients, which could be diversiform and vary at different stages of the clinical course. Although lab investigations and neuro-imaging findings may help quantify the disease's risk, progress and prognosis, large-scale and persistent multicenter clinical cohort studies are needed to evaluate the impact of COVID-19 on the N/P systems. However, we used "Boolean Operators" to search for relevant research articles, reviews and clinical trials from PubMed and the ClinicalTrials dataset for "COVID-19 sequelae of N/P systems during post-COVID periods" with the time frame from December 2019 to April 2022, only found 42 in 254,716 COVID-19-related articles and 2 of 7931 clinical trials involved N/P sequelae during post-COVID periods. Due to the increasing number of infected cases and the incessant mutation characteristics of this virus, diagnostic and therapeutic guidelines for N/P manifestations should be further refined.

Keywords: COVID-19; SARS-CoV-2; neurological; post-COVID; psychiatric; sequelae.

PubMed Disclaimer

Conflict of interest statement

The authors declared that they had no conflict of interest.

Figures

Figure 1
Figure 1
Flow chart of PubMed and clinical Trials studies. COVID-19: All references or trials related to COVID-19; COVID-19-N/P: All references or trials related to COVID-19 with neurological and psychiatric manifestations; COVID-19-N/P-Sequelae: All references or trials related to COVID-19 with neurological and psychiatric manifestations during the post-COVID period.

Similar articles

Cited by

References

    1. AbdelMassih AF, Kamel A, Mishriky F, et al. Is it infection or rather vascular inflammation? Game-changer insights and recommendations from patterns of multi-organ involvement and affected subgroups in COVID-19. Cardiovasc Endocrinol Metab. 2020;9(3):110–120. doi:10.1097/XCE.0000000000000211 - DOI - PMC - PubMed
    1. Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in Southern Africa. Nature. 2022;603(7902):679–686. doi:10.1038/s41586-022-04411-y - DOI - PMC - PubMed
    1. Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399(10332):1303–1312. doi:10.1016/S0140-6736(22)00462-7 - DOI - PMC - PubMed
    1. Krutikov M, Stirrup O, Nacer-Laidi H, et al. Outcomes of SARS-CoV-2 omicron infection in residents of long-term care facilities in England (VIVALDI): a prospective, cohort study. Lancet Healthy Longev. 2022;3(5):e347–e355. doi:10.1016/S2666-7568(22)00093-9 - DOI - PMC - PubMed
    1. Solomon T. Neurological infection with SARS-CoV-2 - the story so far. Nat Rev Neurol. 2021;17(2):65–66. doi:10.1038/s41582-020-00453-w - DOI - PMC - PubMed